Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

Blood stage of Plasmodium vivax in central China is still susceptible to chloroquine plus primaquine combination therapy.

Zhu G, Lu F, Cao J, Zhou H, Liu Y, Han ET, Gao Q.

Am J Trop Med Hyg. 2013 Jul;89(1):184-7. doi: 10.4269/ajtmh.12-0683.

2.

Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia.

Yeshiwondim AK, Tekle AH, Dengela DO, Yohannes AM, Teklehaimanot A.

Acta Trop. 2010 Feb;113(2):105-13. doi: 10.1016/j.actatropica.2009.10.001.

PMID:
19835832
3.
4.

Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India.

Rishikesh K, Kamath A, Hande MH, Vidyasagar S, Acharya RV, Acharya V, Belle J, Shastry AB, Saravu K.

Malar J. 2015 Aug 11;14:310. doi: 10.1186/s12936-015-0824-y. Erratum in: Malar J. 2016;15:59.

5.

Therapeutic responses of Plasmodium vivax malaria to chloroquine and primaquine treatment in northeastern Myanmar.

Yuan L, Wang Y, Parker DM, Gupta B, Yang Z, Liu H, Fan Q, Cao Y, Xiao Y, Lee MC, Zhou G, Yan G, Baird JK, Cui L.

Antimicrob Agents Chemother. 2015 Feb;59(2):1230-5. doi: 10.1128/AAC.04270-14.

6.

Clinical efficacy of chloroquine followed by primaquine for Plasmodium vivax treatment in Azerbaijan.

Valibayov A, Abdullayev F, Mammadov S, Gasimov E, Sabatinelli G, Kondrachine AV, Ringwald P.

Acta Trop. 2003 Sep;88(1):99-102.

PMID:
12943984
7.

In vivo therapeutic efficacy of chloroquine alone or in combination with primaquine against vivax malaria in Kolkata, West Bengal, India, and polymorphism in pvmdr1 and pvcrt-o genes.

Ganguly S, Saha P, Guha SK, Das S, Bera DK, Biswas A, Kundu PK, Saha B, Ray K, Maji AK.

Antimicrob Agents Chemother. 2013 Mar;57(3):1246-51. doi: 10.1128/AAC.02050-12.

8.

In vivo sensitivity monitoring of chloroquine for the treatment of uncomplicated vivax malaria in four bordered provinces of Thailand during 2009-2010.

Congpuon K, Satimai W, Sujariyakul A, Intanakom S, Harnpitakpong W, Pranuth Y, Cholpol S, Bualombai P.

J Vector Borne Dis. 2011 Dec;48(4):190-6.

9.
10.

Assessment of therapeutic efficacy of chloroquine for vivax malaria in Thailand.

Vijaykadga S, Rojanawatsirivej C, Congpoung K, Wilairatana P, Satimai W, Uaekowitchai C, Pumborplub B, Sittimongkol S, Pinyorattanachote A, Prigchoo P.

Southeast Asian J Trop Med Public Health. 2004 Sep;35(3):566-9.

PMID:
15689067
11.

Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico.

Gonzalez-Ceron L, Rodriguez MH, Sandoval MA, Santillan F, Galindo-Virgen S, Betanzos AF, Rosales AF, Palomeque OL.

Malar J. 2015 Oct 30;14:426. doi: 10.1186/s12936-015-0938-2.

12.

Monitoring Plasmodium vivax chloroquine sensitivity along China-Myanmar border of Yunnan Province, China during 2008-2013.

Liu H, Yang HL, Tang LH, Li XL, Huang F, Wang JZ, Li CF, Wang HY, Nie RH, Guo XR, Lin YX, Li M, Xu JW.

Malar J. 2014 Sep 15;13:364. doi: 10.1186/1475-2875-13-364.

13.

Treatment of vivax malaria on the western border of Thailand.

Luxemburger C, van Vugt M, Jonathan S, McGready R, Looareesuwan S, White NJ, Nosten F.

Trans R Soc Trop Med Hyg. 1999 Jul-Aug;93(4):433-8.

PMID:
10674098
14.

Efficacy and safety of chloroquine for treatment in patients with uncomplicated Plasmodium vivax infections in endemic countries.

Naing C, Aung K, Win DK, Wah MJ.

Trans R Soc Trop Med Hyg. 2010 Nov;104(11):695-705. doi: 10.1016/j.trstmh.2010.08.009. Review.

PMID:
20850161
15.

In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia.

Hwang J, Alemayehu BH, Reithinger R, Tekleyohannes SG, Takele Teshi, Birhanu SG, Demeke L, Hoos D, Melaku Z, Kassa M, Jima D, Malone JL, Nettey H, Green M, Poe A, Akinyi S, Udhayakumar V, Kachur SP, Filler S.

PLoS One. 2013 May 22;8(5):e63433. doi: 10.1371/journal.pone.0063433.

16.

Resistance of infection by Plasmodium vivax to chloroquine in Bolivia.

Añez A, Moscoso M, Laguna Á, Garnica C, Melgar V, Cuba M, Gutierrez S, Ascaso C.

Malar J. 2015 Jul 1;14:261. doi: 10.1186/s12936-015-0774-4.

17.

A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia.

Pasaribu AP, Chokejindachai W, Sirivichayakul C, Tanomsing N, Chavez I, Tjitra E, Pasaribu S, Imwong M, White NJ, Dondorp AM.

J Infect Dis. 2013 Dec 1;208(11):1906-13. doi: 10.1093/infdis/jit407.

18.

Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.

Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, Arthur P, Chuenchom N, Möhrle JJ, Duparc S, Ugwuegbulam C, Kleim JP, Carter N, Green JA, Kellam L.

Lancet. 2014 Mar 22;383(9922):1049-58. doi: 10.1016/S0140-6736(13)62568-4.

PMID:
24360369
19.

Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.

Walsh DS, Wilairatana P, Tang DB, Heppner DG Jr, Brewer TG, Krudsood S, Silachamroon U, Phumratanaprapin W, Siriyanonda D, Looareesuwan S.

Clin Infect Dis. 2004 Oct 15;39(8):1095-103.

Items per page

Supplemental Content

Support Center